CDK4 and non-small cell lung carcinoma: One such example is the CDK4/6 inhibitor palbociclib, which has shown efficacy in NSCLC patients with KRAS mutations [66] but performed poorly in cases with CDKN2A mutations or in LUSCs with CCND1-3/CDK4 amplifications [67].